CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD

20Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Creutzfeldt–Jakob disease and Alzheimer's disease are characterized by the presence of elevated total-Tau cerebrospinal fluid concentrations while the presence of hyperphosphorylated Tau forms in the cerebrospinal fluid is rather a hallmark of Alzheimer's disease. Here we aimed to investigate potential contribution of nonphospho-Tau epitopes (non-P-Tau) in the discrimination between both diseases. Non-P-Tau cerebrospinal fluid concentration was highly increased in Creutzfeldt–Jakob disease (n = 57, 3683 ± 3599 pg/mL) compared to Alzheimer's disease (n = 41, 148 ± 219 pg/mL) and neurological controls (n = 56, 62 ± 40 pg/mL), and significantly improved the proportion of correctly classified patients (99%) compared to that achieved by total-Tau (90%), P-Tau (62%) and 14-3-3 (91%).

Cite

CITATION STYLE

APA

Ermann, N., Lewczuk, P., Schmitz, M., Lange, P., Knipper, T., Goebel, S., … Llorens, F. (2018). CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD. Annals of Clinical and Translational Neurology, 5(7), 883–887. https://doi.org/10.1002/acn3.584

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free